Merck and Kelun-Biotech revealed Phase 3 breast cancer data for the lead antibody-drug conjugate in their potentially $12 billion partnership. In a Phase 3 trial for locally recurrent or ...

Senate Finance Committee Chair Ron Wyden (D-OR) is urging HHS to take a stronger stance on healthcare companies' cybersecurity practices as the healthcare system is still piecing together what ...

A New Jersey federal judge on Monday tossed cases brought by Johnson & Johnson and Bristol Myers Squibb against the Inflation Reduction Act, another victory for the law while Medicare ...

Bristol Myers Squibb said its KRAS cancer drug Krazati met the primary endpoint in a Phase 3 confirmatory trial in patients with non-small cell lung cancer, according to new data ...

Madrigal Pharmaceuticals is “making great progress” on the rollout of its NASH drug Rezdiffra, executives said less than a month post-launch. Rezdiffra was approved in March as ...

Small molecule biotech Totus Medicines has closed a $66 million Series B to carry its PI3Kα inhibitor through Phase Ia and has named Nassim Usman as its new president and ...

Plus, news about Oruka Therapeutics, Centessa, Takeda, Innate Pharma and Liquidia: GSK’s mRNA flu vaccine succeeds against both strains in Phase 2: The pharma company ...

ARCH Venture Partners plans to raise $3 billion for its 13th fund, per a new SEC filing from this week. The Chicago-based venture capital firm has ...

Reps. Kelly Armstrong (R-ND) and Ben Cline (R-VA) sent a letter last week to Attorney General Merrick Garland, asking why the Department of Justice is willing to incur potential patent ...

To help meet the heightened demand for its injectable products, Eli Lilly is acquiring a facility from Nexus Pharmaceuticals, with production anticipated to start at the end of next year ...

Below are notable updates from the American Academy of Dermatology’s annual meeting over the weekend: Sanofi amends trial protocol Sanofi has big plans for amlitelimab, the monoclonal antibody ...

Boehringer Ingelheim has acquired University of Basel spinout T3 Pharmaceuticals for 450 million CHF ($507.4 million) in an effort to expand its immuno-oncology portfolio with T3 ...